BNP Paribas Financial Markets Raises Stake in Alphatec Holdings, Inc. (NASDAQ:ATEC)

BNP Paribas Financial Markets lifted its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 73.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 21,603 shares of the medical technology company’s stock after purchasing an additional 9,165 shares during the quarter. BNP Paribas Financial Markets’ holdings in Alphatec were worth $120,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Algert Global LLC purchased a new position in Alphatec in the third quarter valued at about $1,452,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Alphatec by 1.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 823,222 shares of the medical technology company’s stock worth $4,577,000 after acquiring an additional 15,577 shares during the period. Intech Investment Management LLC purchased a new position in Alphatec in the 3rd quarter valued at approximately $189,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in Alphatec by 11.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock worth $16,280,000 after purchasing an additional 297,850 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in Alphatec during the third quarter worth $686,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ATEC. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Friday, August 30th. Barclays lifted their price objective on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a report on Thursday, October 31st. Lake Street Capital reduced their price objective on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $13.00 target price on shares of Alphatec in a research note on Thursday, October 31st. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Alphatec presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.11.

Alphatec Trading Down 7.4 %

Shares of ATEC opened at $8.82 on Thursday. The stock’s fifty day simple moving average is $8.14 and its 200 day simple moving average is $8.12. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $17.34. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The firm has a market capitalization of $1.25 billion, a P/E ratio of -6.89 and a beta of 1.38.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.